What types of policy changes does BCBS Tennessee issue?

BCBS Tennessee regularly publishes coverage updates including prior authorization requirement changes, billing code additions or deletions, plan-type coverage modifications, and clinical policy revisions. PolicyChanges.app monitors these notices and summarizes the impact for providers.

How often does BCBS Tennessee update its policies?

BCBS Tennessee typically releases policy bulletins on a rolling basis throughout the year. Our system checks for new updates daily and adds them to this feed as soon as they are identified.

How many BCBS Tennessee policy changes are tracked here?

This page currently tracks 50 documented BCBS Tennessee policy changes. New items are added as they are identified.

What should I do when BCBS Tennessee changes a prior authorization policy?

Review each change's effective date and action-required notes. Update your billing and clinical workflows before the effective date to avoid claim denials. Each policy detail page on PolicyChanges.app includes a plain-English summary and action items.

BCBS Tennessee Policy Changes 2026 | Prior Auth & Coverage Updates

BCBS Tennessee Policy Changes & Prior Auth Updates

We track 50 documented policy changes from BCBS Tennessee across TN. Each entry includes an AI-generated plain-English summary, effective date, affected billing codes, and a direct link to the original BCBS Tennessee notice. Use the related links below to narrow results by specialty or state, or sign up for a free daily alert to receive new BCBS Tennessee updates automatically.

High impact

Intravenous Immune Globulin (IVIG) - Alyglo™ (Immune Globulin Intravenous (Human)-stwk) Asceniv™ (Immune Globulin Intravenous (Human) - slra); Bivigam®; Flebogamma® DIF; Gammagard® Liquid; Gammagard® Liquid ERC; Gammagard® S/D; Gammaked™; Gammaplex®; Gamunex®-C; Octagam®; Panzyga ® (Immune Globulin Intravenous (Human) - ifas); Privigen®; Qivigy® (Immune Globulin Intravenous (Human) - kthm); Yimmugo® (Immune Globulin Intravenous (Human) - dira)

BCBS Tennessee·Effective Jun 30, 2026

New comprehensive policy for Intravenous Immune Globulin (IVIG) therapy covering 14 different IVIG products with detailed prior authorization requirements for both FDA-approved and compendial uses. The policy establishes specific coverage criteria and documentation requirements for various conditions including primary immunodeficiency, ITP, CIDP, and multiple other indications.

Tocilizumab (Actemra®); Tocilizumab-anoh (Avtozma®); Tocilizumab-bavi (Tofidence™); Tocilizumab-aazg (Tyenne®), tocilizumab-aazg, tocilizumab-anoh

Temozolomide (Temodar®)

Secukinumab (Cosentyx®)

Pembrolizumab (Keytruda®)

Obinutuzumab (Gazyva®)

Histrelin Acetate (Supprelin®LA)

Fam-trastuzumab Deruxtecan-nxki (Enhertu®)

Durvalumab (Imfinzi®)

Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza™)

Atezolizumab (Tecentriq®)

Compression Pumps

Secukinumab (Cosentyx®)

Inclisiran (Leqvio®)

Zenocutuzumab-zbco (Bizengri®)

Verteporfin (Visudyne®)

Triptorelin (Triptodur®)

Triamcinolone Acetonide Injectable Suspension (Xipere®)

Tremelimumab-actl (Imjudo®)

Tildrakizumab-asmn (IIumya®)

Teprotumumab-trbw (Tepezza®)

Siltuximab (Sylvant™)

Sacituzumab Govitecan-hziy (Trodelvy®)

Ramucirumab (Cyramza®)

Pertuzumab, Trastuzumab and Hyaluronidase-zzxf (Phesgo™)

Pertuzumab (Perjeta®); Pertuzumab-dpzb (Poherdy®)

Pembrolizumab and Berahyaluronidase alfa-pmph (Keytruda Qlex™)

Mogamulizumab-kpkc (Poteligeo®)

Luspatercept-aamt (Reblozyl®)

Leuprolide Acetate Depot Suspension (Lupron Depot-Ped®)

Laronidase (Aldurazyme®

Ixabepilone (Ixempra®)

Ipilimumab (Yervoy®)

Imetelstat (Rytelo™

Idursulfase (Elaprase®)

Galsulfase (Naglazyme®)

Eribulin Mesylate (Halaven®)

Epcoritamab-bysp (Epkinly™)

Datopotamab Deruxtecan-dlnk (Datroway®)

Cipaglucosidase Alfa-atga (Pombiliti™)

Beremagene Geperpavec-svdt (Vyjuvek™)

Belimumab (Benlysta®)

Azacitidine (Vidaza®)

Anifrolumab-fnia (Saphnelo®)

Carfilzomib (Kyprolis®)

Bevacizumab Products (Avastin®; Mvasi® ; Zirabev™; Alymsys®; Vegzelma™, Avzivi®, Jobevne™)

Commercial BlueCare PAD_Step Therapy Guide

Pembrolizumab (Keytruda®)

Nivolumab (Opdivo®)